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permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.SUMMARYNANOG is a divergent homeobox protein and a core component of the transcriptional circuitry that sustains pluripotency and
self-renewal. Although NANOG has been extensively studied on the transcriptional level, little is known regarding its posttranslational
regulation, likely due to its low abundance and challenging physical properties. Here, we identify eleven phosphorylation sites on
endogenous human NANOG, nine of which mapped to single amino acids. To screen for the signaling molecules that impart these
modifications, we developed themultiplexed assay for kinase specificity (MAKS).MAKS simultaneously tests activity for up to ten kinases
while directly identifying the substrate and exact site of phosphorylation. Using MAKS, we discovered site-specific phosphorylation
by ERK2 and CDK1/CyclinA2, providing a putative link between key signaling pathways and NANOG.INTRODUCTION
Phosphorylation is a pervasive form of cell signaling that
orchestrates numerous processes, including metabolism,
cell mobility, cell cycle, and differentiation (Brumbaugh
et al., 2011; Van Hoof et al., 2009; Xu and Fisher, 2012).
Mass spectrometryhas revealed the complexity of thephos-
phoproteome in pluripotent cells with great detail (Mun˜oz
and Heck, 2011; Phanstiel et al., 2011; Rigbolt et al., 2011;
Swaney et al., 2009; Van Hoof et al., 2009); however, deter-
mining the biological relevance of such data remains a
major challenge. Mapping the kinases responsible for a
specific phosphorylation event is instructive because it
places that information in the context of signaling mole-
cules that direct biological function. Traditionally, kinase
assays are performed by detecting the transfer of a radioac-
tive phosphoryl group to a given substrate following an
in vitro reaction. This method provides a direct measure
of phosphorylation but necessitates the use of hazardous
materials, cannot directly localize phosphorylation to a sin-
gle aminoacidwhenmore thanonepotential site is present,
and cannot multiplex kinases and substrates. Recently, a
mass-spectrometricmethodwas introduced toprofile phos-
phorylation on synthetic peptides treated with cell lysates
(Yu et al., 2009). This method is ideal for profiling cell-
type-specific phosphorylation, but does not directly deter-
mine the kinase responsible for phosphorylation. Another
method assesses kinase activity but relies upon heavy18 Stem Cell Reports j Vol. 2 j 18–25 j January 14, 2014 j ª2014 The Authorisotope-labeled amino acids and is limited to testing one
or two kinases at a time (Singh et al., 2012b). Several other
methods have been developed to identify kinase consensus
motifs or test a single kinase, but are not capable of multi-
plexed analysis (Hennrich et al., 2013; Kettenbach et al.,
2012; Songyang et al., 1994; Xue et al., 2012). Thus, there
remains a pressing need for a high-throughput method to
screen for kinase(s) that phosphorylate a protein of interest.
In pluripotent cells, phosphorylation has a central role
in directing cell identity by relaying growth-factor sig-
naling through key pathways (i.e., fibroblast growth factor
[FGF] and transforming growth factor b [TGF-b]) (Chen
et al., 2011; Singh et al., 2012a; Vallier et al., 2005; Yu
et al., 2011). The ultimate targets of these phosphorylation
cascades are largely unknown, although recent works have
provided some direction by mapping phosphorylation on
the pluripotency factors OCT4 and SOX2 (Brumbaugh
et al., 2012; Jeong et al., 2010; Phanstiel et al., 2011).
Conspicuously absent in these studies is NANOG, a diver-
gent homeobox transcription factor that promotes plurip-
otency by binding to DNA and regulating the expression
of genes related to cell fate (Boyer et al., 2005; Chambers
et al., 2003; Mitsui et al., 2003; Pan and Thomson, 2007).
In mice, overexpression of NANOG permits extended
culture of undifferentiated embryonic stem cells (ESCs)
in the absence of otherwise obligatory extrinsic signaling
factors such as LIF and BMP4 (Chambers et al., 2003;
Pan and Thomson, 2007). Correspondingly, NANOGs
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Figure 1. Mass Spectrometry Identifies Phosphorylation on Human NANOG
(A) NANOG phosphorylation sites.
(B) The contribution to either sequence coverage or phosphorylation site identification for samples digested with trypsin or GluC.
(C) Representative spectrum showing unambiguous localization of phosphorylation on Ser71. Neutral loss (asterisk) and internal frag-
ments are annotated.
(D) Schematic of NANOG with functional domains. Question marks denote phosphorylation sites that were indistinguishable between
adjacent residues.
See also Figures S1 and S2, and Table S1.
Stem Cell Reports
Phosphorylation of Human NANOGoverexpression in human ESCs obviates the requirement
for exogenous signaling through feeder cells in basal media
or FGF in defined culture systems (Darr et al., 2006; Xu
et al., 2008). Hence, NANOG has a conserved role in
mediating growth-factor signals that are critical for plurip-
otency, and, intriguingly, its overexpression is sufficient
to bypass these signaling pathways to maintain the ESC
state. Still, a direct link between NANOG and the signaling
molecules that determine cell state remains elusive.
In mouse, NANOG protein levels are dynamic (Cham-
bers et al., 2007), and it was recently proposed that NANOG
stability is tied to phosphorylation (Moretto-Zita et al.,
2010). Several studies suggested that mouse NANOG exists
as a phosphoprotein (Li et al., 2011; Moretto-Zita et al.,
2010; Yates and Chambers, 2005); however, its unique
primary sequence and relatively low abundance make it
difficult to purify and detect in a physiologically relevant
context (i.e., without overexpression and in pluripotent
cell types). As a result, there are currently no known phos-
phorylation sites for NANOG from human pluripotent
stem cells and only a single site for endogenous mouseStemNANOG (Li et al., 2011). To address this gap, we applied
high-resolution mass spectrometry to show that NANOG
is heavily phosphorylated at proline-directed sites on its
N terminus. To place these modifications in the context
of signalingmolecules, we developed themultiplexed assay
for kinase specificity (MAKS), and found that ERK2 and
CDK1 differentially phosphorylate NANOG in vitro.RESULTS
Identification of NANOG Phosphorylation Sites
Due to the underrepresentation of NANOG in proteomic
data sets, we adapted a highly efficient purification strategy
that combines high-detergent lysis with multiple forms of
affinity chromatography (see Supplemental Experimental
Procedures available online; Brumbaugh et al., 2012).
Consistent with previous results, traditional digestion
methods that utilize trypsin in preparation for mass spec-
trometry yielded only one phosphopeptide identification
(Figures 1A and 1B). Inspection of the primary sequenceCell Reports j Vol. 2 j 18–25 j January 14, 2014 j ª2014 The Authors 19
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Phosphorylation of Human NANOGfor NANOG revealed that tryptic cleavage sites were tightly
clustered at the center of the protein, with few sites near
either termini, resulting in a limited number of peptides
that were amenable to mass spectrometry (Figure S1). We
therefore tested several alternate proteases and found that
GluC provided superior sequence coverage (Figures 1C
and 1D; Swaney et al., 2010). In total, we sequenced over
40% of the endogenous NANOG protein and identified
11 phosphorylation sites (<1% false discovery rate), nine
of which localized to a single residue (Figure 1D; Table
S1). Note that the exact site of phosphorylation could not
be distinguished between Ser22/23 and Ser68/69 by our
stringent criteria, but were localized to adjacent residues
in each case. Figure 1C shows a representative spectrum
with a fully annotated, localized modification; all spectra
were manually validated to confirm each phosphorylation
site (Figure S2). Many of the peptides identified from
this region were multiply phosphorylated, indicating
that endogenous NANOG is hyperphosphorylated in the
pluripotent state.
To place NANOG phosphorylation sites in the context of
cell signaling, we used the Motif-X program to search for
kinase motifs in our data set (Schwartz and Gygi, 2005).
Intriguingly, a preponderance of NANOG’s phosphory-
lation sites were proline directed (xP) and matched the
minimal ERK motif (5/11 sites; Figure 1B) (Songyang
et al., 1996). This finding is compelling from a biological
standpoint because NANOG overexpression sustains plu-
ripotency upon ERK inhibition (Xu et al., 2008) and activa-
tion of ERK2 maintains NANOG, even in differentiating
cells (Yu et al., 2011). Further computational analysis using
the NetPhorest platform substantiated the hypothesis
that ERK2 phosphorylates these sites, but also pointed to
CDK1 as a possible modifying enzyme (Miller et al.,
2008). Note that these kinases share similar motifs, and
the importance of applying both experimental and com-
putational methods to determine kinase-substrate rela-
tionships has been documented (Linding et al., 2007).
Thus, it is important to directly screen for the kinases
that modify NANOG.
MAKS
To directly identify kinases that target specific residues on
NANOG, we developed a mass-spectrometric approach
called MAKS. This in vitro assay leverages isobaric tagging
technology to monitor the activity of up to ten kinases in
a single experiment. In the first step, candidate kinases,
ATP, and reaction buffer are added to purified protein(s)
in separate but otherwise identical reactions (Figure 2A).
Following incubation, each sample is digested in prepara-
tion for mass spectrometry and labeled with a different
isobaric tag. This tag imparts a unique chemical signature
to every peptide, linking it to the kinase-substrate reaction20 Stem Cell Reports j Vol. 2 j 18–25 j January 14, 2014 j ª2014 The Authorfrom which it originated. Samples are combined and sub-
jected to quantitative tandem mass spectrometry to
directly identify peptide sequences and sites of phosphory-
lation. During peptide fragmentation, the isobaric tags are
cleaved, generating reporter ions that are detected in the
low-mass region of tandem mass spectra (Figure 2B). The
intensity of these reporter ions functions as a readout
for the abundance of phosphorylated peptides from the
corresponding kinase reaction.
MAKS Reveals Site-Specific Phosphorylation by ERK2
and CDK1 on NANOG
We selected AKT1, AKT2, CDK1/CyclinA2, CDK5/p35,
ERK2, and PKA as candidate kinases for NANOG modifica-
tion.We chose these kinases based primarily onmotif anal-
ysis for phosphorylation sites on NANOG (ERK2 and
CDK1/5), but also considered kinases involved in pluripo-
tency and differentiation (AKT1/2 and PKA). This selection
of kinases also covered candidates from both the AGC
and CMCG kinase families. All kinases were active and
capable of phosphorylating numerous control substrates
(Table S2). We therefore performed our in vitro assay by
incubating each kinase with full-length, recombinant
NANOG. Following mass spectrometry, reporter ion inten-
sities were mean normalized and adjusted using nonphos-
phorylated peptides to correct for pipetting error and
sample loss (see Experimental Procedures; Figure S3A). In
total, we quantified five phosphorylation sites, all of which
corresponded to modifications on the endogenous protein
(Figures 3 and S3B). As shown in Figure 3, ERK2 demon-
strated a clear preference for Ser52, a putative ERK site
that was also identified on the endogenous protein (Fig-
ure 3B). The abundance of phosphorylation for Ser52 was
5-fold higher for the ERK2 channel than for the next-
closest channel. Interestingly, our data also showed that
Ser71, another putative ERK site identified on endogenous
NANOG, was instead preferentially phosphorylated by
CDK1/CyclinA2 (Figure 3C), while Ser65 was modified
by both ERK2 and CDK1/CyclinA2 (Figure S3B). This
demonstrates the remarkable specificity achieved through
this simple assay and also illustrates the importance of
determining phosphorylation for individual sites. Phos-
phorylation at Ser23 and Ser258 was similar across all
kinases (Figures 3D and S3B), suggesting that (1) a different
kinase is responsible for phosphorylation at these sites, (2)
cofactors not included in this assay are required for
specificity, or (3) these sites can be phosphorylated by
a variety of kinases. Importantly, this shows that the
specificity observed at Ser52 and Ser71 is not the result of
higher activity for the respective kinases. Phosphorylation
sites that were identified on the endogenous protein
but not quantified in the MAKS assay may be subject to
regulation by kinases that were not included in our panel,s
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Figure 2. A Simplified Schematic for MAKS
(A) Identical protein samples are treated separately with kinases, labeled, and mixed prior to analysis. A six-plex experiment is shown, but
ten samples can be simultaneously assayed.
(B) Peptide identity and phosphorylation site localization are determined using tandem mass spectrometry. Reporter tags are cleaved
during tandem mass spectrometry and appear in the low-mass range (liftout). The relative intensity for each reporter tag is directly
proportional to the amount of phosphorylation contributed by the corresponding kinase.
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Phosphorylation of Human NANOGor may require additional cofactors and/or subcellular
localization.DISCUSSION
Together with OCT4 and SOX2, NANOG functions as a key
transcriptional regulator in pluripotency. To date, almost
no information is available regarding posttranslational
regulation of NANOG. Our data show that NANOG is
multiply phosphorylated in human ESCs. Nine of 11 sites
were observed in a serine/threonine-rich patch from resi-
dues 50–79, suggesting that this region may serve as a
regulatory cluster. In support of this notion, recent compu-
tational work identified a putative PEST sequence (residuesStem47–72) on NANOG that overlaps greatly with the hyper-
phosphorylated region (Figure 1D; Ramakrishna et al.,
2011). Deletion of the PESTsequence alteredNANOGubiq-
uitination and degradation (Ramakrishna et al., 2011).
Further,mutational analysis inmouse for sites homologous
to Ser52, Ser65, and Ser71 suggested that phosphorylation
of these residues stabilizes NANOG (Moretto-Zita et al.,
2010). All of these results point to a role for this region in
regulating NANOG protein levels. Our data provide direct
evidence that these regulatory sites are phosphorylated
on human NANOG and in a physiological context. The
function of phosphorylation at Ser22/23 and Ser258 is
currently unclear; however, Ser258 is located in the CD2
activation domain and may modulate NANOG’s ability to
activate transcription (Do et al., 2009). Further work willCell Reports j Vol. 2 j 18–25 j January 14, 2014 j ª2014 The Authors 21
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Figure 3. ERK2 and CDK1 Specifically Phosphorylate Different Sites on NANOG
(A) Mass spectrum from a typical kinase assay with Ser52 phosphorylation. Neutral loss (asterisk) is annotated. The liftout shows a zoomed
view of the reporter ion region.
(B) ERK2 preferentially phosphorylates Ser52.
(C) CDK1 specifically phosphorylates Ser71.
(D) No kinase tested shows a preference for Ser258. Bar graphs represent the normalized abundance of at least three PSMs. Error bars
represent the SD calculated from at least three PSMs across three independent experiments. The dashed line indicates the level that would
be expected if the contribution for all channels were equal.
See also Figure S3 and Table S2.
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Phosphorylation of Human NANOGbe needed to clarify the exact role of each modification
identified here.
For years, FGF has been a requisite component in human
pluripotent stem cell media (Chen et al., 2011; Ludwig
et al., 2006), and yet the mechanism by which FGF
supports pluripotency was unknown. Our data show that
ERK2, a downstream effector in the FGF pathway, directly22 Stem Cell Reports j Vol. 2 j 18–25 j January 14, 2014 j ª2014 The Authorphosphorylates NANOG at Ser52. A recent report demon-
strated that phosphorylation of a homologous site on
mouse NANOG facilitated interaction with Pin1, a prolyl
isomerase that inhibits ubiquitination and subsequent
proteosomal degradation by inducing conformational
changes (Moretto-Zita et al., 2010). Together, these data
suggest that ERK2 phosphorylation positively regulatess
Stem Cell Reports
Phosphorylation of Human NANOGNANOG by increasing its stability. The interplay between
ERK and CDK signaling is also interesting in the context
of pluripotency. Our data show that these kinases phos-
phorylate similar sequences on NANOG that are separated
by only 19 amino acids. This result raises the possibility
that CDK1 functions analogously to ERK, perhaps to sus-
tain NANOG during S/M phase; however, this is only
speculative at this point.
MAKS provides a multiplexed strategy for simulta-
neously screening multiple kinases and protein substrates.
A major advantage of this assay is its capacity to directly
assess kinase activity for individual phosphorylation sites.
In the case of NANOG, this feature enabled us to dissect
the specificity of ERK2 and CDK1/CyclinA2, even on
nearby sites. This specificity may result from three-dimen-
sional protein structure or cooperation with CyclinA2,
although it is also possible that the primary sequence
alone is sufficient to direct kinase activity. In this regard,
a further benefit of MAKS is that it allows one to carry
out kinase assays using whole proteins as a substrate.
This preserves a potential phosphorylation site in the
context of adjacent residues or protein structure. Other
cofactors, subcellular localization, or additional modi-
fications may be necessary to confer specificity. MAKS
provides a means to test the role of many of these addi-
tional components, which can be added or removed
from the kinase reaction to determine their effect. The
multiplexing capacity is only limited by the number of
isobaric tags available from the manufacturer (currently
ten tags are commercially available), and because sub-
strates are directly identified via mass spectrometry,
multiple proteins of interest can be analyzed in a single
reaction.
We note that the MAKS assay applies relative quantita-
tion and therefore requires careful selection of candidate
kinases. In some instances, for example, a physiological
kinase for a given substrate may be absent from the panel
tested. In such cases, MAKS will identify the kinase
that exhibits the highest activity for a given substrate, if
indeed there is a preference among the kinases tested.
Computational methods will be critical for selecting the
most likely candidate kinases, and testing a wide variety
of kinases should help in identifying the most relevant
kinases. To this end, we are currently working to couple
kinase panels to automated mass spectrometry to increase
the throughput of the MAKS assay and expand the
number of kinases that can be tested to hundreds of
kinases. The MAKS approach should also be applicable
to any protein-modifying enzyme (i.e., acetylase, methyl-
transferase, etc.). Together, the simplicity and multiplex-
ing capabilities of this assay make MAKS widely applicable
in screening for enzymes that modify a substrate of
interest.StemEXPERIMENTAL PROCEDURES
Kinase Assays
Kinase assays were carried out in 25 mM MOPS, pH 7.2, 12.5 mM
beta-glycerol-phosphate, 25mMMgCl2, 5mMEGTA, 2mMEDTA,
1 mM dithiothreitol (DTT), and 0.1 mM ATP. Approximately 1 mg
of recombinant NANOG and 0.25 mg of AKT1, AKT2, CDK1,
CDK5, or ERK2 (all from Promega), or 2.5 U of PKA (Sigma) were
added for 30 min at 23C. For control reactions, 0.5 mg of
maltose-binding protein (MBP) and histone H1 (SignalChem)
were added in place of NANOG. The reactions were then treated
with 5 mM DTT at 37C for 30 min, 10 mM iodoacetamide in
the dark at 23C for 30 min, and 10 mM DTT at 23C for 30 min.
Proteins were digested with GluC or chymotrypsin (both
from Roche Diagnostics) at an enzyme-to-protein ratio of 1:200,
purified by solid-phase extraction, and labeled with TMT
isobaric tags (Thermo-Fisher) according to the manufacturer’s
recommendations.Data analysis
Phosphosite localization was evaluated using Phosphinator soft-
ware (Swaney et al., 2009). This algorithm processes the theoret-
ical fragment ion m/z ratios for all possible permutations of
phosphopeptide isoforms based on sequence and the number
of phosphorylation sites. It then compares each experimental
spectrum to the theoretical product ions using a product mass
tolerance of ± 0.02 Th. Phosphinator determines the significance
of observed product ions that designate phosphorylation at a
given amino acid. A localized site must have a p value of <0.05
for consideration. Further details about this algorithm were previ-
ously described (Swaney et al., 2009). Each localized phosphosite
reported by Phosphinator was manually validated. Other high-
scoring spectra with unlocalized phosphosites (as reported by
Phosphinator) were manually interrogated to determine whether
localization could be achieved. Theoretical product ions from
other candidate phospho-isoforms were generated using the MS
Product program in Protein Prospector (http://prospector.ucsf.
edu/prospector/cgi-bin/msform.cgi?form=msproduct), and locali-
zation and spectral chimerism were evaluated (Clauser et al.,
1999). In all cases, product ions were required to be within 15
ppm of the theoretical m/z with a signal-to-noise ratio R 3 to
be used for sequence assignment. Both neutral loss product
ions and internal fragments were considered during manual
validation in addition to standard b- and y-type ions (HCD)
and c- and z-type product ions (ETD).
TMT isotope purity corrections were applied using the TagQuant
program in COMPASS (Wenger et al., 2011). Purity-corrected tag
intensities were mean normalized for all peptide spectral matches
(PSMs). We then took advantage of E. coli proteins that copurified
with recombinant NANOG to further correct for pipetting error
and sample loss. Briefly, E. coli PSMs were filtered to eliminate
any peptide hit that contained a potential phosphorylation site
(STY) or exhibited greater than 25% interference. The values
for each channel were then averaged to establish the mean bias
for that channel. Dividing one by each mean bias generated
correction factors, which were used to normalize the quantitative
values for each channel.Cell Reports j Vol. 2 j 18–25 j January 14, 2014 j ª2014 The Authors 23
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